Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
NCT02869425 · RVL Pharmaceuticals, Inc. · PHASE3 · withdrawn · last registry update 2022-04-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “suspended due to inability to enroll subjects” | – | Registry record, RVL Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-15Also stopped (withdrawn): University Hospital, Ghent, Sodium oxybate + Placebo (NCT01584934)
- 2022-09-28Results posted on the registry: Baylor College of Medicine, sodium oxybate (NCT00641186)
- 2022-08-26Phase 3 first posted: Tanta University, Baclofen Tablets (NCT05516953)
- 2022-07-15Results posted on the registry: RVL Pharmaceuticals, Inc., Arbaclofen (NCT03319732)
- 2022-07-15Results posted on the registry: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT03290131)
- 2022-04-29Also stopped (terminated): Mansoura University, Orphenadrine + Baclofen (NCT04509336)
- 2022-04-08Results posted on the registry: UCB Pharma SA, Sodium Oxybate (Xyrem) (NCT00345800)
- 2022-03-22Results posted on the registry: Avadel, FT218 + Placebo (NCT02720744)
- 2022-01-05Phase 3 first posted: RVL Pharmaceuticals, Inc., Arbaclofen + Placebo (NCT05179577)
- 2021-11-24Results posted on the registry: Children's Hospital Medical Center, Cincinnati, Acamprosate + Lovastatin (NCT02998151)
- 2021-10-26Phase 3 first posted: Tasly GeneNet Pharmaceuticals Co., Ltd, PXT3003 + PXT3003 placebo (NCT05092841)
- 2021-04-27Results posted on the registry: Vanderbilt University, Baclofen bolus injection (NCT02903823)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision